AIM ImmunoTech completes Phase 2 DURIPANC trial enrollment milestone for Ampligen-Imfinzi combo in metastatic pancreatic cancer

AIM ImmunoTech Inc. Common Stock

AIM

0.00

AIM ImmunoTech completed enrollment in its Phase 2 DURIPANC trial of Ampligen with Imfinzi for metastatic pancreatic cancer, ahead of schedule.
Positive year-end interim results were already presented; the next interim update is expected within two to three weeks.
The study remains on track for a December 2026 readout of its primary endpoint, focused on whether patients maintain meaningful disease control.
AIM expects to finish dosing all subjects in August, supporting Phase 3 planning for Ampligen in pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606010858PRIMZONEFULLFEED9729364) on June 01, 2026, and is solely responsible for the information contained therein.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.